Localization of regional lymph nodes in melanomas of the head and neck

James C. Alex, David N. Krag, Seth P. Harlow, Sybren Meijer, Brian W. Loggie, Joseph Kuhn, Michele Gadd, Donald L. Weaver

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objectives: To study the efficacy of gamma-probe radiolocalization of the first draining (sentinel) lymph node (SLN) in stage NO melanoma of the head an neck and to evaluate its potential role in the staging and treatment of this disease. Design: Gamma-probe radiolocalization, a new alternative to blue-dye lymphatic mapping, uses a scintillation (gamma) probe to identify radiolabeled SLNs. In a consecutive sample clinical trial, gamma-probe radiolocalization of the SLN is compared with lymphoscintigraphy and blue- dye lymphatic mapping. Follow-ups ranged from 1.7 years to 4 years, with a mean follow-up of 2.5 years. Setting: Tertiary and private care teaching hospital. Patients: Between June 1993 and November 1995, 23 patients with stage NO intermediate-thickness melanoma of the head and neck were enrolled in this volunteer sample. Interventions: Twenty-four hours prior to surgery, a radioactive tracer was intradermally injected around the circumference of a primary melanoma. Twelve patients also had blue dye injected just prior to surgical resection. Using a handheld gamma probe, radiolabeled lymph nodes were identified and selectively removed with minimal dissection. In patients with nodes with histologic evidence of metastases, a regional lymphadenectomy was performed. Main Outcome Measures: The successful identification of radiolabeled SLNs, the correlation of SLN radiolabeling to lymphoscintigraphy and blue-dye mapping, and the long-term development of regional metastases. Results: Surgeons successfully resected the radiolabeled SLNs in 22 (96%) of 23 patients. The success rate of blue-dye lymphatic mapping was 8 (75%) of 12 patients and lymphoscintigraphy was 20 (91%) of 22 patients. One hundred percent of blue-stained lymph nodes were radiolabaled. The one patient in whom no SLN could be identified developed regional disease at 17 months. Conclusions: Gamma-probe radiolocalization and resection of the radiolabeled SLN is a simple and reliable method of staging regional lymph nodes and determining the need for elective lymphadenectomy.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume124
Issue number2
StatePublished - Feb 1998
Externally publishedYes

Fingerprint

Melanoma
Neck
Lymph Nodes
Head
Lymphoscintigraphy
Coloring Agents
Lymph Node Excision
Radioactive Tracers
Neoplasm Metastasis
Tertiary Healthcare
Teaching Hospitals
Dissection
Volunteers
Outcome Assessment (Health Care)
Sentinel Lymph Node
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Alex, J. C., Krag, D. N., Harlow, S. P., Meijer, S., Loggie, B. W., Kuhn, J., ... Weaver, D. L. (1998). Localization of regional lymph nodes in melanomas of the head and neck. Archives of Otolaryngology - Head and Neck Surgery, 124(2), 135-140.

Localization of regional lymph nodes in melanomas of the head and neck. / Alex, James C.; Krag, David N.; Harlow, Seth P.; Meijer, Sybren; Loggie, Brian W.; Kuhn, Joseph; Gadd, Michele; Weaver, Donald L.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 124, No. 2, 02.1998, p. 135-140.

Research output: Contribution to journalArticle

Alex, JC, Krag, DN, Harlow, SP, Meijer, S, Loggie, BW, Kuhn, J, Gadd, M & Weaver, DL 1998, 'Localization of regional lymph nodes in melanomas of the head and neck', Archives of Otolaryngology - Head and Neck Surgery, vol. 124, no. 2, pp. 135-140.
Alex, James C. ; Krag, David N. ; Harlow, Seth P. ; Meijer, Sybren ; Loggie, Brian W. ; Kuhn, Joseph ; Gadd, Michele ; Weaver, Donald L. / Localization of regional lymph nodes in melanomas of the head and neck. In: Archives of Otolaryngology - Head and Neck Surgery. 1998 ; Vol. 124, No. 2. pp. 135-140.
@article{3638239d316b47c1b9aff4c25dd32da8,
title = "Localization of regional lymph nodes in melanomas of the head and neck",
abstract = "Objectives: To study the efficacy of gamma-probe radiolocalization of the first draining (sentinel) lymph node (SLN) in stage NO melanoma of the head an neck and to evaluate its potential role in the staging and treatment of this disease. Design: Gamma-probe radiolocalization, a new alternative to blue-dye lymphatic mapping, uses a scintillation (gamma) probe to identify radiolabeled SLNs. In a consecutive sample clinical trial, gamma-probe radiolocalization of the SLN is compared with lymphoscintigraphy and blue- dye lymphatic mapping. Follow-ups ranged from 1.7 years to 4 years, with a mean follow-up of 2.5 years. Setting: Tertiary and private care teaching hospital. Patients: Between June 1993 and November 1995, 23 patients with stage NO intermediate-thickness melanoma of the head and neck were enrolled in this volunteer sample. Interventions: Twenty-four hours prior to surgery, a radioactive tracer was intradermally injected around the circumference of a primary melanoma. Twelve patients also had blue dye injected just prior to surgical resection. Using a handheld gamma probe, radiolabeled lymph nodes were identified and selectively removed with minimal dissection. In patients with nodes with histologic evidence of metastases, a regional lymphadenectomy was performed. Main Outcome Measures: The successful identification of radiolabeled SLNs, the correlation of SLN radiolabeling to lymphoscintigraphy and blue-dye mapping, and the long-term development of regional metastases. Results: Surgeons successfully resected the radiolabeled SLNs in 22 (96{\%}) of 23 patients. The success rate of blue-dye lymphatic mapping was 8 (75{\%}) of 12 patients and lymphoscintigraphy was 20 (91{\%}) of 22 patients. One hundred percent of blue-stained lymph nodes were radiolabaled. The one patient in whom no SLN could be identified developed regional disease at 17 months. Conclusions: Gamma-probe radiolocalization and resection of the radiolabeled SLN is a simple and reliable method of staging regional lymph nodes and determining the need for elective lymphadenectomy.",
author = "Alex, {James C.} and Krag, {David N.} and Harlow, {Seth P.} and Sybren Meijer and Loggie, {Brian W.} and Joseph Kuhn and Michele Gadd and Weaver, {Donald L.}",
year = "1998",
month = "2",
language = "English",
volume = "124",
pages = "135--140",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Localization of regional lymph nodes in melanomas of the head and neck

AU - Alex, James C.

AU - Krag, David N.

AU - Harlow, Seth P.

AU - Meijer, Sybren

AU - Loggie, Brian W.

AU - Kuhn, Joseph

AU - Gadd, Michele

AU - Weaver, Donald L.

PY - 1998/2

Y1 - 1998/2

N2 - Objectives: To study the efficacy of gamma-probe radiolocalization of the first draining (sentinel) lymph node (SLN) in stage NO melanoma of the head an neck and to evaluate its potential role in the staging and treatment of this disease. Design: Gamma-probe radiolocalization, a new alternative to blue-dye lymphatic mapping, uses a scintillation (gamma) probe to identify radiolabeled SLNs. In a consecutive sample clinical trial, gamma-probe radiolocalization of the SLN is compared with lymphoscintigraphy and blue- dye lymphatic mapping. Follow-ups ranged from 1.7 years to 4 years, with a mean follow-up of 2.5 years. Setting: Tertiary and private care teaching hospital. Patients: Between June 1993 and November 1995, 23 patients with stage NO intermediate-thickness melanoma of the head and neck were enrolled in this volunteer sample. Interventions: Twenty-four hours prior to surgery, a radioactive tracer was intradermally injected around the circumference of a primary melanoma. Twelve patients also had blue dye injected just prior to surgical resection. Using a handheld gamma probe, radiolabeled lymph nodes were identified and selectively removed with minimal dissection. In patients with nodes with histologic evidence of metastases, a regional lymphadenectomy was performed. Main Outcome Measures: The successful identification of radiolabeled SLNs, the correlation of SLN radiolabeling to lymphoscintigraphy and blue-dye mapping, and the long-term development of regional metastases. Results: Surgeons successfully resected the radiolabeled SLNs in 22 (96%) of 23 patients. The success rate of blue-dye lymphatic mapping was 8 (75%) of 12 patients and lymphoscintigraphy was 20 (91%) of 22 patients. One hundred percent of blue-stained lymph nodes were radiolabaled. The one patient in whom no SLN could be identified developed regional disease at 17 months. Conclusions: Gamma-probe radiolocalization and resection of the radiolabeled SLN is a simple and reliable method of staging regional lymph nodes and determining the need for elective lymphadenectomy.

AB - Objectives: To study the efficacy of gamma-probe radiolocalization of the first draining (sentinel) lymph node (SLN) in stage NO melanoma of the head an neck and to evaluate its potential role in the staging and treatment of this disease. Design: Gamma-probe radiolocalization, a new alternative to blue-dye lymphatic mapping, uses a scintillation (gamma) probe to identify radiolabeled SLNs. In a consecutive sample clinical trial, gamma-probe radiolocalization of the SLN is compared with lymphoscintigraphy and blue- dye lymphatic mapping. Follow-ups ranged from 1.7 years to 4 years, with a mean follow-up of 2.5 years. Setting: Tertiary and private care teaching hospital. Patients: Between June 1993 and November 1995, 23 patients with stage NO intermediate-thickness melanoma of the head and neck were enrolled in this volunteer sample. Interventions: Twenty-four hours prior to surgery, a radioactive tracer was intradermally injected around the circumference of a primary melanoma. Twelve patients also had blue dye injected just prior to surgical resection. Using a handheld gamma probe, radiolabeled lymph nodes were identified and selectively removed with minimal dissection. In patients with nodes with histologic evidence of metastases, a regional lymphadenectomy was performed. Main Outcome Measures: The successful identification of radiolabeled SLNs, the correlation of SLN radiolabeling to lymphoscintigraphy and blue-dye mapping, and the long-term development of regional metastases. Results: Surgeons successfully resected the radiolabeled SLNs in 22 (96%) of 23 patients. The success rate of blue-dye lymphatic mapping was 8 (75%) of 12 patients and lymphoscintigraphy was 20 (91%) of 22 patients. One hundred percent of blue-stained lymph nodes were radiolabaled. The one patient in whom no SLN could be identified developed regional disease at 17 months. Conclusions: Gamma-probe radiolocalization and resection of the radiolabeled SLN is a simple and reliable method of staging regional lymph nodes and determining the need for elective lymphadenectomy.

UR - http://www.scopus.com/inward/record.url?scp=0031887618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031887618&partnerID=8YFLogxK

M3 - Article

VL - 124

SP - 135

EP - 140

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 2

ER -